Drug Patents owned by Mayne Pharma
1. Drug name - DORYX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6958161 | MAYNE PHARMA | Modified release coated drug preparation |
Dec, 2022
(2 months from now) | |
| US8715724 | MAYNE PHARMA | Tabletting process |
Feb, 2028
(5 years from now) | |
| US9511031 | MAYNE PHARMA | Controlled release doxycycline |
Oct, 2034
(12 years from now) | |
| US9295652 | MAYNE PHARMA | Controlled release doxycycline |
Oct, 2034
(12 years from now) | |
| US9446057 | MAYNE PHARMA | Controlled release doxycycline |
Dec, 2034
(12 years from now) | |
Drugs and Companies using DOXYCYCLINE HYCLATE ingredient
Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet
Dosage: TABLET, DELAYED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 50MG BASE | TABLET, DELAYED RELEASE;ORAL | Prescription |
| EQ 75MG BASE | TABLET, DELAYED RELEASE;ORAL | Prescription |
| EQ 80MG BASE | TABLET, DELAYED RELEASE;ORAL | Prescription |
| EQ 100MG BASE | TABLET, DELAYED RELEASE;ORAL | Prescription |
| EQ 150MG BASE | TABLET, DELAYED RELEASE;ORAL | Prescription |
| EQ 200MG BASE | TABLET, DELAYED RELEASE;ORAL | Prescription |
| EQ 60MG BASE | TABLET, DELAYED RELEASE;ORAL | Discontinued |
| EQ 120MG BASE | TABLET, DELAYED RELEASE;ORAL | Prescription |
2. Drug name - FABIOR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10568859 | MAYNE PHARMA | Topical foam composition |
Feb, 2030
(7 years from now) | |
| US10688071 | MAYNE PHARMA | Topical foam composition |
Feb, 2030
(7 years from now) | |
| US8808716 | MAYNE PHARMA | Topical foam composition |
Feb, 2030
(7 years from now) | |
Drugs and Companies using TAZAROTENE ingredient
Treatment: Topical treatment of acne vulgaris in patients 12 years of age or older
Dosage: AEROSOL, FOAM;TOPICAL
| Strength | Dosage | Availability |
|---|---|---|
| 0.1% | AEROSOL, FOAM;TOPICAL | Prescription |
3. Drug name - LEXETTE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10857159 | MAYNE PHARMA | Halobetasol foam composition and method of use thereof |
Nov, 2036
(14 years from now) | |
| US11020407 | MAYNE PHARMA | Corticosteroid containing foam compositions and method of manufacture thereof |
Nov, 2036
(14 years from now) | |
|
US10857159
(Pediatric) | MAYNE PHARMA | Halobetasol foam composition and method of use thereof |
May, 2037
(14 years from now) | |
Drugs and Companies using HALOBETASOL PROPIONATE ingredient
Treatment: For the topical treatment of plaque psoriasis in patients 18 years of age and older
Dosage: AEROSOL, FOAM;TOPICAL
| Strength | Dosage | Availability |
|---|---|---|
| 0.05% | AEROSOL, FOAM;TOPICAL | Prescription |
4. Drug name - NEXTSTELLIS
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7732430 | MAYNE PHARMA | Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception |
Mar, 2025
(2 years from now) | |
Drugs and Companies using DROSPIRENONE; ESTETROL ingredient
Treatment: Use by females of reproductive potential to prevent pregnancy
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 3MG;14.2MG | TABLET;ORAL | Prescription |
5. Drug name - SORILUX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8629128 | MAYNE PHARMA | Vitamin formulation |
May, 2026
(3 years from now) | |
| US8263580 | MAYNE PHARMA | Vitamin formulation |
May, 2028
(5 years from now) | |
Drugs and Companies using CALCIPOTRIENE ingredient
Treatment: Use of a calcipotriene containing foam for the treatment of psoriasis; use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 18 years and older; use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 4 years and older; Use of a calcipotriene containing foam for the treatment of psoriasis; use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 4 years and older
Dosage: AEROSOL, FOAM;TOPICAL
| Strength | Dosage | Availability |
|---|---|---|
| 0.005% | AEROSOL, FOAM;TOPICAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.